Caveolin-3 inhibits growth signal in cardiac myoblasts in a Ca 2+-dependent manner

Journal of Cellular and Molecular Medicine

Volumn 10, Issue 1, 2006, Pages 216-224

  Fujita, Takayuki ^a   Otsu, Kouji ^a   Oshikawa, Jin ^a   Hori, Hideaki ^a   Kitamura, Hitoshi ^a   Ito, Takaaki ^a   Umemura, Satoshi ^a   Minamisawa, Susumu ^a   Ishikawa, Yoshihiro ^a,b,c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcineurin; Caveolin 3; H9C2 cells; Protein kinase C

Indexed keywords

ANGIOTENSIN DERIVATIVE; CALCINEURIN; CALCIUM; CAVEOLIN 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C;

ANIMAL; ARTICLE; CAVEOLA; CELL CLONE; CELL LINE; CELL PROLIFERATION; DRUG ANTAGONISM; METABOLISM; MYOBLAST; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION;

ANGIOTENSINS; ANIMALS; CALCINEURIN; CALCIUM; CAVEOLAE; CAVEOLIN 3; CELL LINE; CELL PROLIFERATION; CLONE CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MYOBLASTS, CARDIAC; PROTEIN KINASE C; RATS; SIGNAL TRANSDUCTION;

EID: 33748345801     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2006.tb00302.x     Document Type: Article

References (24)

1. Sargiacomo M, Sudol M, Tang Z, Lisanti M. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol. 1993; 122: 789-807.
2. Song K, Scherer P, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz D, Lisanti M. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996; 271: 15160-5.
3. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova J, Hansen S, Nishimoto I, Lisanti M. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem. 1995; 270: 15693-701.
4. Li S, Couet J, Lisanti M. Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996; 271: 29182-90.
5. Engelman J, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz D, Lisanti M. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 1998; 428: 205-11.
6. Toya Y, Schwencke C, Couet J, Lisanti M, Ishikawa Y. Inhibition of adenylyl cyclase by caveolin peptides. Endocrinology 1998; 139: 2025-31.
7. Razani B, Zhang X, Bitzer M, von Gersdorff G, Bottinger E, Lisanti M. Caveolin-1 regulates transforming growth factor (TGF)-β/SMAD signaling through an interaction with the TGF-β type I receptor. J Biol Chem. 2001;276:6727-38.
8. Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S, Couet J, Lisanti M, Ishikawa Y. Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem. 1997; 272: 33416-21.
9. Park W, Cho K, Park J, Kim D, Park S. Attenuation of EGF signaling in senescent cells by caveolin. Ann N Y Acad Sci. 2001; 928.
10. Yamamoto M, Toya Y, Jensen RA, Ishikawa Y. Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res. 1999; 247: 380-8.
11. Molkentin J, Dorn IGn. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001; 63: 391-426.
12. Ostrom RS. Caveolins muscle their way into the regulation of cell differentiation, development, and function. Focus on "Muscle-specific interaction of caveolin isoforms: differential complex formation between caveolins in fibroblastic vs. muscle cells." Am J Physiol Cell Physiol. 2005; 288: C507-9.
13. Koga A, Oka N, Kikuchi T, Miyazaki H, Kato S, Imaizumi T. Adenovirus-mediated overexpression of caveolin-3 inhibits rat cardiomyocyte hypertrophy. Hypertension 2003; 42: 213-9.
14. Dodge KL, Scott JD. Calcineurin anchoring and cell signaling. Biochem Biophys Res Commun. 2003; 311: 1111-5.
15. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-28.
16. Taigen T, De Windt LJ, Lim HW, Molkenrin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA. 2000; 97: 1196-201.
17. nd, Kitsis RN, Molkentin JD. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. Circ Res. 2000; 86: 255-63.
18. Sabri A, Steinberg SF. Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem. 2003; 251: 97-101.
19. Taggart MJ, Leavis P, Feron O, Morgan KG. Inhibition of PKCα and rhoA translocation in differentiated smooth muscle by a caveolin scaffolding domain peptide. Exp Cell Res. 2000; 258: 72-81.
20. Fujita T, Toya Y, Iwatsubo K, Onda T, Kimura K, Umemura S, Ishikawa Y. Accumulation of molecules involved in α1-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. Cardiovasc Res. 2001; 51: 709-16.
21. De Windt LJ, Lim HW, Haq S, Force T, Molkentin JD. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem. 2000; 275: 13571-9.
22. Avraham A, Jung S, Samuels Y, Seger R, Ben-Neriah Y. Co-stimulation- dependent activation of a JNK-kinase in T lymphocytes. Eur J Immunol. 1998; 28: 2320-30.
23. Werlen G, Jacinto E, Xia Y, Karin M. Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. EMBO J. 1998; 17: 3101-11.
24. Levy D, Garrison R, Savage D, Kannel W, Castelli W. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561-6.